


## Rivaroxaban-d<sub>4</sub>

Cat. No.:	HY-50903S		
CAS No.:	1132681-38-9		
Molecular Formula:	C <sub>19</sub> H <sub>14</sub> D <sub>4</sub> ClN <sub>3</sub> O <sub>5</sub> S		
Molecular Weight:	439.91		
Target:	Factor Xa		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (113.66 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.2732 mL	11.3660 mL	22.7319 mL
5 mM	0.4546 mL	2.2732 mL	4.5464 mL
10 mM	0.2273 mL	1.1366 mL	2.2732 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Rivaroxaban-d<sub>4</sub> is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent and selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC<sub>50</sub> 0.7 nM; Ki 0.4 nM)[1][2].

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 0.7 nM (Factor Xa); Ki: 0.4 nM (Factor Xa)[1][2]

### CUSTOMER VALIDATION

- Molecules. 2023 Feb 28.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

---

[1]. Roehrig S, et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. *J Med Chem.* 2005 Sep 22;48(19)

[2]. Perzborn E, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. *J Thromb Haemost.* 2005 Mar;3(3):514-21.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA